Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

CPI-203

Catalog No: tcsc2190

Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg

Size: 25mg

Specifications

CAS No:
1446144-04-2

Formula:
$C_{19}H_{18}ClN_5OS$

Pathway:
Epigenetics

Target:
Epigenetic Reader Domain

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 47 mg/mL (117.53 mM)

Observed Molecular Weight:
399.9

Product Description

CPI-203 is a novel potent, selective and cell permeable inhibitor of **BET bromodomain**, with an **IC_{50}** value of appr 37 nM (BRD4 α-

screen assay).

IC50 & Target: IC50: 37 nM (BRD4)

In Vitro: CPI203 inhibits BRD4 in vitro and in cells, but does not affect BRD4 kinase activity in vitro[1]. CPI203 exerts a cytostatic effect in all the 9 MCL cell lines analyzed with GI_{50} ranging from 0.06 to 0.71 μM, with low cytotoxicity in normal PBMCs from healthy donors. Furthermore, lenalidomide and CPI203, by targeting IRF4 and MYC, efficiently activates the cell death program in MCL cells resistant to bortezomib[2].

In Vivo: BRD4 mediates CTD Ser2 phosphorylation in vivo[1]. In REC-1 tumor-bearing mice, the combination of lenalidomide with CPI203 (2.5 mg/kg, i.p.) synergistically augments the antitumoral properties of each single agent via the abrogation of MYC and IRF4 expression and the induction of apoptosis[2].